Last reviewed · How we verify
ALK Grass tablet
ALK Grass tablet is an allergen immunotherapy that desensitizes the immune system to grass pollen allergens through gradual exposure.
ALK Grass tablet is an allergen immunotherapy that desensitizes the immune system to grass pollen allergens through gradual exposure. Used for Grass pollen-induced allergic rhinitis and/or allergic asthma.
At a glance
| Generic name | ALK Grass tablet |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Allergen immunotherapy (sublingual tablet) |
| Target | Grass pollen allergens (multiple epitopes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
This sublingual immunotherapy tablet contains standardized grass pollen allergen extract designed to induce immune tolerance. By administering small, gradually increasing doses of the allergen under the tongue, the treatment shifts the immune response from allergic (Th2-mediated) to tolerant (Th1/Treg-mediated), reducing allergic symptoms upon natural grass pollen exposure.
Approved indications
- Grass pollen-induced allergic rhinitis and/or allergic asthma
Common side effects
- Oral pruritus
- Throat irritation
- Mouth edema
- Local allergic reactions at administration site
Key clinical trials
- Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT (PHASE2, PHASE3)
- Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen (NA)
- A Trial of the ALK Grass Tablet in Subjects With Hayfever (PHASE3)
- Assessment of Grazax® Treatment Compliance (PHASE3)
- Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets (PHASE3)
- Tolerability of Grazax-R in Children (PHASE1)
- Tolerability of ALK Grass Tablet in Children (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |